Although the level of glycated hemoglobin (HbA 1C ) reflects chronic glycemic control, treatment-induced decreases in HbA 1C in patients who have established diabetes do not always predict beneficial clinical outcomes. Clinical outcomes are dramatically influenced by the history of previous glycemic control, the extent of current clinical complications, and the side effects of therapeutic agents. Rational approaches to the intensity of glycemic control in individual patients should take these factors into consideration, as well as in setting an appropriate goal for the HbA 1C target.
The Rate of Development of Chronic Vascular Complications in Patients with Diabetes Should Be Linearly Related to the Level of HbA 1C
If this were true, a decrease in HbA 1C of 1 % should give the same absolute rate of reduction of vascular complications independent of the baseline HbA 1C value. In fact, the DCCT study showed that risk reduction is curvilinear (see Figure 1) Other studies have shown that hypoglycemia significantly increases the corrected QT interval (QTc).
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Conclusions and Recommendations
Obviously, HbA 1C is a reliable measure of glycemic control and a useful tool for assessing chronic management. The problem is that glycemic control itself has been assumed to always determine clinical outcomes.
Based on the evidence, it is apparent that this is not true. Equally important to clinical outcomes is the stage of vascular disease at the time of the glycemic control, as well as the nature and severity of side effects of the agents being used to control the glycemia. Aggressive lowering of HbA 1C to values between 6.5 % and 7.0 % in patients having minimal vascular disease, by means of agents having minimal side effects, is supported by the available data. By contrast, such aggressive lowering with agents that cause hypoglycemia and weight gain and/or that facilitate fluid retention in patients having diabetes and significant cardiovascular disease or risk for cardiovascular disease has a high likelihood of causing detrimental, rather than beneficial, effects.
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In such patients, maintaining glycemic control at a moderate level (7.5 %) using agents that do not cause hypoglycemia or weight gain and that are not detrimental to the cardiovascular system is likely to benefit the patient. What is yet to be determined is whether lowering HbA 1C to 7.0 % or lower using agents that have minimal or no metabolic side effects is beneficial to patients having diabetes and significant chronic vascular complications. In evaluating treatment options for glycemic control, it is as important to select therapies by their potential side effects as by their ability to provide a 0.2-0.4 % greater decrease in HbA 1C .
The greatest clinical benefit of an HbA 1C target <7 % is at the onset of diabetes, and the value lessens with increasing duration of poor control.
Rational approaches to glycemic control in patients having diabetes are those that improve clinical outcomes and quality of life. n (Source: Diabetes, 1995; 44:968-83 
